Cuál es el precio por Metagenomi, Inc. Common Stock (MGX)

Precio por Metagenomi, Inc. Common Stock (MGX) es de$1.21

Cuál es la capitalización de mercado por Metagenomi, Inc. Common Stock (MGX)

Capitalización de mercado por Metagenomi, Inc. Common Stock (MGX) es $45.36M

Metagenomi, Inc. Common Stock (MGX) Rendimiento por Dividendo

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Año	Rendimiento por dividendo	Cambiar
Not enough data for the provided dates.

Año

Rendimiento por dividendo

Cambiar

Not enough data for the provided dates.

Empresa	Rendimiento por dividendo	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH
Moderna, Inc. MRNA.US	0.00%	US

Empresa

Rendimiento por dividendo

País